ArticleJID innovations : skin science from molecules to population health2025
Evaluation of Actinic Keratosis as a Risk Factor for Subsequent Nonskin Cancer Risk.
Article in JID innovations : skin science from molecules to population health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Actinic keratosis (AK) is a precancerous lesion that develops on chronically sun-exposed skin. Immunosuppression is known to increase the risk of both AK and other cancers, highlighting the need to evaluate potential associations between AK and subsequent nonskin cancers. To determine whether a diagnosis of AK is associated with an increased subsequent incident of nonskin cancers, we conducted a retrospective case-control study within a large integrated healthcare delivery system. The study included 53,778 patients with AK and 152,896 controls without prior cancer diagnoses at enrollment. AK was more prevalent in males (30.7 vs 23.5% in females). AK was not associated with increased risk of overall nonskin cancers after adjusting for demographic (age, sex), clinical (body mass index, immunosuppression history), behavioral (smoking, alcohol use), and healthcare utilization factors (adjusted hazard ratio = 0.99, 95% confidence interval = 0.95-1.02). However, significant associations were observed between AK and breast (adjusted hazard ratio = 1.11, 95% confidence interval = 1.03-1.19) and prostate (adjusted hazard ratio =1.14, 95% confidence interval = 1.03-1.26) cancers. This large study reveals that AK may be a predictor of risk for subsequent cancers, notably breast and prostate cancers. These findings emphasize the need for increased surveillance for these cancer types in individuals with AK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.